Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma.
Weiner
M A
MA
Harris
M B
MB
Lewis
M
M
Jones
R
R
Sherry
H
H
Feurer
E J
EJ
Johnson
J
J
Lahman
E
E
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005121:Extremities; D005500:Follow-Up Studies; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery
D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate